CINECA IRIS Institutional Research Information System

BERTINARIA, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.963
EU - Europa 2.813
AS - Asia 1.916
OC - Oceania 36
AF - Africa 34
SA - Sud America 26
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.860
CN - Cina 981
IT - Italia 806
SG - Singapore 338
IE - Irlanda 334
SE - Svezia 314
DE - Germania 251
UA - Ucraina 186
GB - Regno Unito 178
FR - Francia 164
FI - Finlandia 141
KR - Corea 115
IN - India 105
PL - Polonia 96
VN - Vietnam 93
AT - Austria 85
CA - Canada 84
JP - Giappone 83
ID - Indonesia 64
BE - Belgio 49
DK - Danimarca 43
AU - Australia 33
CH - Svizzera 32
HK - Hong Kong 32
NL - Olanda 29
IR - Iran 26
TW - Taiwan 20
RU - Federazione Russa 19
MX - Messico 17
TR - Turchia 17
ES - Italia 16
BR - Brasile 15
RO - Romania 14
SN - Senegal 14
GR - Grecia 12
IL - Israele 9
UZ - Uzbekistan 9
CZ - Repubblica Ceca 8
EG - Egitto 7
HU - Ungheria 7
TH - Thailandia 7
LT - Lituania 6
PT - Portogallo 6
EU - Europa 5
NG - Nigeria 5
NO - Norvegia 5
AL - Albania 4
CL - Cile 4
MY - Malesia 4
NZ - Nuova Zelanda 3
RS - Serbia 3
ZA - Sudafrica 3
IQ - Iraq 2
PK - Pakistan 2
QA - Qatar 2
SA - Arabia Saudita 2
SC - Seychelles 2
UY - Uruguay 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BG - Bulgaria 1
BJ - Benin 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
YE - Yemen 1
Totale 9.793
Salva come PNG Salva come JPEG
Città #
Chandler 708
Ann Arbor 408
Dublin 330
Santa Clara 328
Beijing 305
Singapore 274
Ashburn 229
Fairfield 228
Torino 172
Houston 158
Jacksonville 149
Wilmington 142
Woodbridge 133
Nyköping 127
Turin 110
Dearborn 99
Seattle 91
Medford 88
Redwood City 87
Pisa 84
Villeurbanne 84
Warsaw 82
Princeton 81
Vienna 81
Columbus 80
Cambridge 74
Shanghai 66
Boardman 62
Dong Ket 62
Jakarta 61
Guangzhou 55
Milan 54
Fremont 52
Brussels 43
Nanjing 43
Rome 43
New York 38
Munich 29
Ottawa 27
Toronto 27
Hangzhou 26
Helsinki 25
Boston 24
Pune 23
Shenyang 23
San Diego 22
Tokyo 21
Jinan 20
Los Angeles 19
Hefei 18
Zhengzhou 18
London 17
Mumbai 17
Seongnam 15
Seoul 15
Chengdu 14
Frankfurt am Main 14
Tübingen 13
Washington 13
Brisbane 12
Harbin 12
Lansing 12
Nottingham 12
Nuremberg 12
Verona 12
Wuhan 12
Xian 12
Amsterdam 11
Hong Kong 11
Philadelphia 11
Pittsburgh 11
Fuzhou 10
Hyderabad 10
San Jose 10
Athens 9
Baltimore 9
Changsha 9
Hebei 9
Norwalk 9
Taipei 9
Belfast 8
Central 8
Changchun 8
Chongqing 8
Lachine 8
Xi'an 8
Zurich 8
Düsseldorf 7
Hanoi 7
Mountain View 7
Nagoya 7
New Delhi 7
Rochester 7
Cosenza 6
Dallas 6
Hamburg 6
Naples 6
Palermo 6
Phoenix 6
Portiragnes 6
Totale 6.115
Salva come PNG Salva come JPEG
Nome #
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis 628
Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells from Type2 Diabetes Patients: Rescue by alpha Ketoglutarate and TET-TDG Functional Reactivation 458
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition 367
Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways 321
Development of covalent NLRP3 inflammasome inhibitors: chemistry and biological activity 314
In the search for new NLRP3 inhibitors: chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2 Hbenzo[d]imidazole-2-one scaffold 306
Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury? 279
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors. 270
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity 234
Edaravone derivatives containing NO-donor functions 221
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile 219
Nonsteroidal anti-inflammatory drugs: Exploiting bivalent COXIB/TP antagonists for the control of cardiovascular risk 177
Composti ibridi per il trattamento della malaria cerebrale 173
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria 172
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis 170
A rapid screening for cytochromes P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives 168
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 149
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors 144
Design and synthesis of N-benzoyl amino acid derivatives as DNA methylation inhibitors 139
A new class of NO-donor H3-Antagonists 135
Amphiphilic NO-Donor Antioxidants 134
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents 128
Design, Synthesis and Pharmacological Evaluation of Anti-Pyroptotic Compounds Acting on NLRP3 Inflammasome Signaling Pathway: a New Start for Anti-Inflammatory Drugs? 123
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 119
EXPLORING THE AMYLOID BETA (ABETA) DEPENDENT METABOLIC FINGERPRINT OF HIPPOCAMPAL NEURONS BY TWO-DIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY: POTENTIALS IN DRUG DISCOVERY STUDIES 118
Synthesis of Small Molecules as Potential DNA Methylation Modulators 118
Carnosine analogues containing Phenol substructures 114
Cardiac Epi-Metabolic Signature Revealed by Integrated Omics Approach in Diabetic Patients: Rescue by Active DNA Demethylation via TET-TDG Complex Reactivation 114
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents 113
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 109
Chemical modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor 105
Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades 105
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives 103
Synthesis and pharmacological characterisation of new H2-antagonists containing NO-donor moieties, endowed with mixed antisecretory and gastroprotective activities. 103
Use of the Morita-Baylis-Hillman reaction in the design of compounds inhibiting NLRP3 inflammasome signaling pathways 102
[3-(1H-Imidazol-4-yl)propyl)guanidines Containing Furoxan Moieties: A New Class of H3-Antagonists Endowed with NO-Donor Properties 101
Anti-Helicobacter pylori Agents Endowed with H2-antagonist Properties 98
Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives 98
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity 95
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury? 95
Targeting NLRP3 inflammasome regulatory mechanisms: design of anti-pyroptotic compounds for autoinflammatory diseases 93
Pharmacological characterization of new NLRP3 inflammasome inhibitors. 93
Synthesis and antimalarial activities of some furoxan sulfones and related furazans 91
NO-donor Carnosine Derivatives As Potential Neuroprotective Agents 90
Use of the furoxan (1,2,5-oxadiazole 2-oxide) system in the design of new NO-donor antioxidant hybrids 86
Synthesis and preliminary evaluation of model compounds targeting the NLRP3 inflammasome pathways 86
Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation 85
Use of the furoxan (1,2,5-oxadiazole 2-oxide)system in the design of new NO-donor antioxidant hybrids 80
Antisecretory and gastroprotective activities of compounds endowed with H2 antagonistic and nitric oxide (NO) donor properties 79
Identification of Small Synthetic Anti-Pyroptotic Compounds 77
Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans 77
Inhibition of NLRP3 ATPase activity: a new strategy to fight chronic inflammatory diseases 77
Furoxan-, alkylnitrate-derivatives and related compoundsas anti-trypanosomatid agents: Mechanism of action studies 75
NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria 74
A New Gateway for Rheumatoid Arthritis: COXIBs with an Improved Cardiovascular Profile 72
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 70
Targeting NLRP3 inflammasome: development of new covalent and non-covalent inhibitors of ATPase activity 70
NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY 69
Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-7 69
EVALUATION OF THE ANTIPYROPTOTIC ACTIVITY OF NEW INFLAMMASOME INHIBITORS 68
Effect of the leaving group on the electrodic reduction mechanism of anti-Helicobacter pylori metronidazole derivatives, in aprotic and protic media 67
In silico study of NLRP3: towards selective inhibition with small molecules 67
New inhibitors of NLRP3 inflammasome activation: pharmacological characterization in differentiated THP-1. 66
Synthesis and Pharmacological Evaluation of Novel H3 Antagonists Endowed with NO-Donor Properties 65
H3 receptor ligands: new imidazole H3-antagonists endowed with NO-donor properties 64
New non-sulfonylurea NLRP3 inhibitors: discovery and selection of INF200, a 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor 62
Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols 61
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein 58
Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation 52
Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isostere 52
Progettazione, sintesi ed attività farmacologica di nuovi ibridi molecolari NO-donatori attivi sul recettore H2 dell'istamina 52
New tools for the development of direct NLRP3 inflammasome inhibitors 52
Non-imidazole histamine NO-donor H3-antagonists 49
Synthesis and anti-helicobacter pylori properties of NO/donor metronidazole hybrids and related compounds 42
Design and synthesis of SWIR emitters for optical imaging 41
Nitric oxide (NO) donor beta(2)-agonists:furoxan derivatives containing the fenoterol moiety and related furazans 39
Design and synthesis of encorafenib-based BRAF-V600E degraders 38
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury? 37
Design and synthesis of INF195, a new NLRP3 Inflammasome Inhibitor with ex vivo cardioprotective effect 34
H3 Receptor Ligands: New Imidazole H3-antagonists Endowed with NO-Donor Properties 34
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study 34
NLRP3 INFLAMMASOME-inhibiting compounds and the use thereof 24
Discovery of a septin-4 covalent binder with antimetastatic activity in a mouse model of melanoma 24
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 24
Inflammasome Inhibitors 22
Design, synthesis and selection of INF200, a new non-sulfonylurea based NLRP3 inhibitor 21
Inflammasome Biology Fundamentals, Role in Disease States, and Therapeutic Opportunities 20
Modulation of the aspartic acid scaffold to identify a new septin-4 covalent binder with anti-metastatic activity in a mouse model of melanoma 19
NLRP3 monomer functional dynamics: From the effects of allosteric binding to implications for drug design 18
Exploring flavylium-based SWIR emitters: Design, synthesis and optical characterization of dyes derivatized with polar moieties 14
Totale 10.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.744
article - articoli 0
book - libri 0
conference - conferenze 8.078
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020783 0 0 0 0 0 143 106 106 148 125 61 94
2020/20211.040 74 68 83 66 104 84 77 63 142 68 69 142
2021/20221.305 60 79 87 90 87 38 99 89 65 98 280 233
2022/20231.977 166 268 80 234 131 479 140 137 176 39 64 63
2023/20241.045 113 159 62 58 75 145 33 88 21 65 75 151
2024/20251.342 81 171 167 255 468 200 0 0 0 0 0 0
Totale 10.072